The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review

Adrian Alfonso Almodovar Diaz, Samhar Samer Alouch, Yogesh Chawla, Wilson I Gonsalves · 2024

Read The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review by Adrian Alfonso Almodovar Diaz, Samhar Samer Alouch, Yogesh Chawla, Wilson I Gonsalves (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11631777.txt.

Description

Adrian Alfonso Almodovar Diaz, Samhar Samer Alouch, Yogesh Chawla, and Wilson Gonsalves review a targeted drug for multiple myeloma, a blood cancer that usually returns after treatment. Their 2024 review focuses on belantamab-mafodotin, the first antibody-drug conjugate aimed at a protein found on malignant plasma cells. Such conjugates pair an antibody with a poison payload, delivered straight to the cancer.

The drug's antibody homes to the target protein, and its payload breaks the cell's internal scaffolding, triggering death. A series of trials, called the DREAMM studies, tested the drug in many settings. The review gathers preclinical and clinical evidence for patients whose disease resisted standard therapies.

Catalog record

CREATORAdrian Alfonso Almodovar Diaz, Samhar Samer Alouch, Yogesh Chawla, Wilson I Gonsalves
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11631777

Browse the full library · About the Tower of Babel